Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 1:2011:318348.
doi: 10.5402/2011/318348. Print 2011.

Prevalence of ESBL-Producing Klebsiella pneumoniae Isolates in Tertiary Care Hospital

Affiliations

Prevalence of ESBL-Producing Klebsiella pneumoniae Isolates in Tertiary Care Hospital

Vemula Sarojamma et al. ISRN Microbiol. .

Abstract

Extended-spectrum β lactamases (ESBLs) continue to be a major challenge in clinical setups world over, conferring resistance to the expanded-spectrum cephalosporins. An attempt was made to study the prevalence of ESBL-producing Klebsiella pneumoniae clinical isolates in a tertiary care hospital in Kurnool. A total of hundred collected isolates of Klebsiella pneumoniae was studied for their susceptibility patterns to various antibiotics and detection of ESBL producers by double disc synergy test (DDST) and phenotypic confirmatory disc diffusion test (PCDDT). Of the 100 isolates tested for their antibiogram, 61% isolates have shown susceptibility to 3rd-generation cepholosporins and 39% were resistant. Amoxycillin showed the highest percentage of resistance followed by tetracyclins and cotrimoxazole. Among 39 resistant isolates of Klebsiella pneumoniae, 17 were ESBL producers detected by DDST and PCDDT. ESBL producers were more in the hospital isolates (28%) compared to community isolates (6%). Maximum percentage of ESBL producers were noticed from blood sample with 57.14%. In the present study, a large number of isolates were found to be multidrug resistant and ESBL producers. PCDDT was found to be better than DDST in the detection of ESBLs. Continued monitoring of drug resistance is necessary in clinical settings for proper disease management.

PubMed Disclaimer

References

    1. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clinical Infectious Diseases. 2003;36(supplement 1):S11–S23. - PubMed
    1. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clinical Microbiology Reviews. 2005;18(4):657–686. - PMC - PubMed
    1. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. The Lancet Infectious Diseases. 2008;8(3):159–166. - PubMed
    1. Steward CD, Wallace D, Hubert SK, et al. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories. Diagnostic Microbiology and Infectious Disease. 2000;38(1):59–67. - PubMed
    1. Gupta V. An update on newer β-lactamases. Indian Journal of Medical Research. 2007;126(5):417–427. - PubMed

LinkOut - more resources